Presidio Pharmaceuticals will return the license rights to the HIV nucleoside reverse transcriptase inhibitor MIV-310 to Sweden’s Medivir.

As a result of this agreement, Medivir will transfer the full license to the compound and intellectual property to Beijing Mefuvir Medicinal Technology, which will develop MIV-310 for use against HIV.

Bo Öberg, Medivir HIV Franchise’s CEO, said the candidate has shown potency against multidrug-resistant HIV in Phase II trials, and the combination of MIV-310 and AZT (zidovudine) shows synergistic effects against the disease.